| Followers | 52 |
| Posts | 14331 |
| Boards Moderated | 0 |
| Alias Born | 06/15/2014 |
Saturday, February 12, 2022 7:45:14 AM
Zip, I ran out of posts quite early yesterday and have been stewing about this all night. I wake up to find your post touch on some of my sentiments.
At the very start, Marjac starts out "..I am going to focus the argument today on 4 broad themes: 1) fraud, 2) mistake, 3) abuse of discretion, 4) institutional integrity". And before another word can come out of Marjac's mouth, he gets barraged with the standing BS. There was even at one point when Marjac is questioned about "only reason you are here is because you did not like the previous verdict" (paraphrase).
Well, for shit's sake isn't that the definition of an appeal and yes I know this is not a pure derivative suit.
So thinking along your lines coupled with the fact that I am very old now and have no patience anymore, if this was a suit where I was only representing myself I would have told those judges interrupting me to look in the damn briefs and let me finish. Of course Marjac was representing many of us and did restrain himself and really did a marvelous job. Imagine that, his first time in front of that court and his performance should be used as an instructing tool.
I think too, that I can't possibly believe, that anyone who listened yesterday, did not come away with being hugely upset with Amarin's legal team and strategy. It is one thing to be worried or ashamed of the mistakes they made in the past, but to not join Marjac's effort means they don't give a shit about the company. I think we know that already by all the actions/non-actions in their day to day management of the company anyway, but it was so glaring yesterday.
At the very start, Marjac starts out "..I am going to focus the argument today on 4 broad themes: 1) fraud, 2) mistake, 3) abuse of discretion, 4) institutional integrity". And before another word can come out of Marjac's mouth, he gets barraged with the standing BS. There was even at one point when Marjac is questioned about "only reason you are here is because you did not like the previous verdict" (paraphrase).
Well, for shit's sake isn't that the definition of an appeal and yes I know this is not a pure derivative suit.
So thinking along your lines coupled with the fact that I am very old now and have no patience anymore, if this was a suit where I was only representing myself I would have told those judges interrupting me to look in the damn briefs and let me finish. Of course Marjac was representing many of us and did restrain himself and really did a marvelous job. Imagine that, his first time in front of that court and his performance should be used as an instructing tool.
I think too, that I can't possibly believe, that anyone who listened yesterday, did not come away with being hugely upset with Amarin's legal team and strategy. It is one thing to be worried or ashamed of the mistakes they made in the past, but to not join Marjac's effort means they don't give a shit about the company. I think we know that already by all the actions/non-actions in their day to day management of the company anyway, but it was so glaring yesterday.
Recent AMRN News
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:04 AM
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 12:05:27 PM
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:17 PM
